NeoGenomics

NeoGenomics, Inc. is a prominent player in the medical testing and clinical laboratory industry, founded in 1999. The company specializes in cancer-focused genetic and molecular testing services, providing critical diagnostic information to hospitals, oncologists, and pharmaceutical researchers. Their technical suite includes cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and next-generation sequencing. These services enable precise cancer care and support pharmaceutical development programs through advanced pathology consultation and reference laboratory capabilities.

Operating with a workforce of 1,000-5,000 employees, NeoGenomics, Inc. maintains a robust operational footprint across 10 locations. Learn about NeoGenomics, Inc.'s global headquarters for geographic details regarding their primary facility in Fort Myers, Florida. The company leverages its extensive network to provide high-quality diagnostic testing, ensuring that clinicians and researchers have access to essential genomic data for patient treatment and clinical trials. Their commitment to innovation and quality standards, including CLIA and CAP certifications, underscores their role in the precision medicine landscape.

In a competitive market, NeoGenomics, Inc. faces industry rivals such as Natera, Exact Sciences, and Myriad Genetics. The company continues to expand its diagnostic information services, focusing on the interpretation of DNA and RNA structures to meet the evolving needs of the oncology sector. Meet NeoGenomics, Inc.'s team to learn about their leadership and organizational structure. By maintaining a focus on specialized oncology diagnostics and contract research, the firm remains a key contributor to the healthcare ecosystem, providing essential testing services that drive advancements in cancer treatment and patient outcomes.